 |
5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate |
|---|---|
| Trade Name | |
| Orphan Indication | Pulmonary Arterial Hypertension |
| USA Market Approval | USA |
| USA Designation Date | 2010-10-21 00:00:00 |
| Sponsor | Forest Laboratories, Inc.;Harborside Financial Center, Plaza V;Jersey City, New Jersey, 07311 |
